Polyvalent Ionizable Lipid Library

Lipid delivery systems containing ionizable lipids have entered broad clinical use with the introduction of the COVID-19 mRNA vaccines and are now generally considered the gold standard for in vivo mRNA delivery.

Our scientists developed a technology that enables rapid screening of a library of polyvalent ionizable lipids to select for potent application-specific lipid formulations⁹.

The Polyvalent Ionizable Lipid Library is protected by a pending U.S. patent (with additional patents pending in other countries).

• Application-specific library screening
• Screening for delivery to target cells and/or tissues
• Combine with Factor’s Chromatin Context-Sensitive Gene-Editing Endonuclease for high-specificity ex vivo or in vivo gene editing
• Protection of nucleic acids from degradation pathways

• Efficient delivery of RNA and/or DNA to a variety of cell types
• Deliver nucleic acids, including mRNA, in vivo
• Combine with Factor’s Engineered Protein-Encoding RNA to streamline manufacturing of nucleic acid therapies